Analysis for KVUE

📈 Growth & Financial Trajectory

Eight quarters show a stable, high-margin consumer health business. Revenue declined modestly from about $4.00B in 2024 Q2 to about $3.91B in 2026 Q4, a drop of roughly -2.5%. Net income attributable to parent rose from about $322M to $474M, up ~47%. Gross margins stayed in the high-50s to low-60s, while operating margins improved from the mid-teens to about 19% by 2026 Q4, signaling stronger operating leverage despite the flatter top line.

💰 Margins & Cash Flow

• Gross margin remains solid, roughly 57-63% across quarters.
• Operating margin expanded toward ~19% in the latest period.
• Net cash flow from operating activities is consistently positive and rising (e.g., about $294M continuing in 2025 Q4 and $489M in 2026 Q4).
• Investing cash flow is negative in most quarters (typical capex/investment activity), around -$90M to -$167M; financing is variable.

🛡️ Balance Sheet & Liquidity

Total assets run around $26-27B with equity near $9.6-10.6B and liabilities around $16-16.3B. Current assets vs current liabilities give a near-1.0x liquidity profile. Leverage is moderate, supported by steady cash flows.

⚠️ Key Drivers & Risks

• Drivers: durable brand portfolio and steady consumer health demand; strong OCF enables deleveraging and share-friendly actions.
• Risks: limited top-line growth, cyclicality in consumer spend, and potential pricing/competition pressure.